Disease overview

Alterations

126

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

104

Natural agents

Natural products

Merged ranked

178

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, GreenMedInfo, Examine.com · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Patchy AA: spontaneous regrowth in 50-80% within 1 year; alopecia totalis/universalis (AT/AU): spontaneous full regrowth <10%; chronic AA (>10 years): spontaneous remission rare

Best-intervention remission

Baricitinib (Olumiant): 38.8% achieving ≥80% scalp coverage (SALT score ≤20) at 36 weeks vs 2% placebo (BRAVE-AA1); ritlecitinib (Litfulo): 23.4% SALT ≤10 at 24 weeks (ALLEGRO); dupilumab: negative Phase 3 for AA (not effective despite positive for AD)

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Very large — JAK inhibitors are transformative but no approved treatment existed before June 2022; most patients previously managed with immunosuppressants with low efficacy and side effects

Primary barrier

access

Barrier detail: Baricitinib (2022) and ritlecitinib (2023) are the first approved treatments specifically for severe AA; prior to this, intralesional corticosteroids and systemic immunosuppressants (cyclosporine, methotrexate) provided variable and non-durable response; cost ($20-25K/year) and durability questions on treatment cessation are key barriers

Last SoC change: 2023 — ritlecitinib (Litfulo) FDA approved for AA (second JAK inhibitor); 2022 baricitinib (Olumiant) — first FDA-approved treatment for AA; prior systemic treatments used off-label

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005340 · ORPHA: ORPHA:1006

Alterations

Showing 80 of 126 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Alopecia totalis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Alopecia universalis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Autoimmunity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nail pits	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Patchy alopecia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Trachyonychia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABCA13 ATP binding cassette subfamily A member 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADGB androglobin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AGAP1 ArfGAP with GTPase domain, ankyrin repeat and PH domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATP2A3 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATXN1 ataxin 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Anagen/telogen ratio	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
BCAR3 BCAR3 adaptor protein, NSP family member	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCL2L14 BCL2 like 14	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BMX BMX non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BTBD9 BTB domain containing 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BTK Bruton tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BZW2 basic leucine zipper and W2 domains 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C11orf87 chromosome 11 open reading frame 87	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C16orf82 chromosome 16 open reading frame 82	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
CADPS calcium dependent secretion activator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK1 checkpoint kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHML CHM like Rab escort protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COL1A1 collagen type I alpha 1 chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CPPED1 calcineurin like phosphoesterase domain containing 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CPQ carboxypeptidase Q	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CPXM2 carboxypeptidase X, M14 family member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CREG2 cellular repressor of E1A stimulated genes 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSMD1 CUB and Sushi multiple domains 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTLA4 cytotoxic T-lymphocyte associated protein 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CTNND2 catenin delta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change From Baseline in Androgenetic Alopecia (AGA) Using the Norwood-Hamilton Scale	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Androgenetic Alopecia (AGA) Using the Sinclair Scale	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change from baseline in hair number	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change from baseline in hair width	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DAB2IP DAB2 interacting protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DST dystonin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Dermatologist Evaluation of Scalp Health (Scale)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Dino-Lite microscopic photographs for terminal hair diameter measurements in the target area.	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
E2F3 E2F transcription factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EPS15 epidermal growth factor receptor pathway substrate 15	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ESRRB estrogen related receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EVC2 EvC ciliary complex subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAM78B family with sequence similarity 78 member B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FER FER tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FRMPD2 FERM and PDZ domain containing 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FRRS1 ferric chelate reductase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GABRB2 gamma-aminobutyric acid type A receptor subunit beta2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GAP43 growth associated protein 43	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLCCI1 glucocorticoid induced 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLP1R glucagon like peptide 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNG12 G protein subunit gamma 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRXCR1 glutaredoxin and cysteine rich domain containing 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GTF3C1 general transcription factor IIIC subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HHAT hedgehog acyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL13 interleukin 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RA interleukin 2 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RB interleukin 2 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RG interleukin 2 receptor subunit gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ITK IL2 inducible T cell kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Incidence of local adverse events	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Investigator Global Assessment: Total Subjects With Slightly Increased Hair Growth or Better Using a Seven-point Rating Scale	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
JAK1 Janus kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK2 Janus kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK3 Janus kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LDB2 LIM domain binding 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LHCGR luteinizing hormone/choriogonadotropin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LMLN leishmanolysin like peptidase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRRC74B leucine rich repeat containing 74B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP7 microtubule associated protein 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MRPS33 mitochondrial ribosomal protein S33	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MTAP methylthioadenosine phosphorylase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MYCN MYCN proto-oncogene, bHLH transcription factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Mean Change From Baseline in Cumulative Target Area Hair Width (TAHW)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Mean Change From Baseline in Target Area Hair Count (TAHC)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
NCOA3 nuclear receptor coactivator 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACALABRUTINIB Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ACALABRUTINIB MALEATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACYCLOVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ASCIMINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AXITINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUSULFAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CABOZANTINIB S-MALATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CELECOXIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CRIZOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ENTRECTINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERLOTINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GENISTEIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYUREA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IBRUTINIB Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMATINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMATINIB MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INOTUZUMAB OZOGAMICIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MELPHALAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NILOTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
ALDESLEUKIN	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BARICITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CLOBETASOL PROPIONATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DEURUXOLITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DIPHENCYPRONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
GARLIC	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
HYDROCORTISONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IVARMACITINIB SULFATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TOFACITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
UPADACITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ABATACEPT	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ABROCITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
AMLITELIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ASLAN-003	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
AZATHIOPRINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BEMPIKIBART	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BETAMETHASONE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BEXAROTENE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BREPOCITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CRISABOROLE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DAXDILIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DELGOCITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DEUCRAVACITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ETRASIMOD	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
IFIDANCITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
MINOXIDIL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
NEOMYCIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
REZPEGALDESLEUKIN	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ROSNILIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
RUXOLITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
RUXOLITINIB PHOSPHATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
SECUKINUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TESNATILIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TOFACITINIB CITRATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TRALOKINUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TRIAMCINOLONE ACETONIDE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
VANCOMYCIN	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE	Small molecule	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets
BETAMETHASONE VALERATE	Small molecule	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACALABRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ACALABRUTINIB MALEATE Repurposing via BTK	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACYCLOVIR Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ASCIMINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AXITINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
AZACITIDINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BLINATUMOMAB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
BOSUTINIB MONOHYDRATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BUSULFAN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CABOZANTINIB S-MALATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CELECOXIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CRIZOTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
DASATINIB ANHYDROUS Repurposing via BTK	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DIAZEPAM Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ENTRECTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
EPIRUBICIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ERLOTINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ETHOXZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLUMAZENIL Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GENISTEIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROXYUREA Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
IBRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMATINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMATINIB MESYLATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
IMIPRAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INOTUZUMAB OZOGAMICIN Repurposing via ABL1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ISOSORBIDE DINITRATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets

Natural Products

19 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Ginseng Natural product Human Study An herbal extract combination (Biochanin A, Acetyl tetrapeptide-3, and… In Vitro Study P. ginseng-derived polyacetylenes with a hydroxyl moiety might provide…	Botanical	Preclinical	Emerging	7	4 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Probiotics Natural product Human Study Kimchi and cheonggukjang probiotic product could promote hair growth an…	Probiotic	Phase III	Emerging	7	5 trials View evidence Registry trials NCT06484881 — Clinical Study of Probiotic Treatment for Androgenetic Alopecia (WITHDRAWN) PHASE3 NCT07370519 — Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia (RECRUITING) PHASE2 NCT05077553 — TCI999 in the Efficacy Verification Program of Hair and Body Health Care (COMPLETED) NA NCT06560385 — Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula (RECRUITING) NA NCT05599607 — Clinical Trial to Evaluate Effectiveness of a Probiotic Preparation Administered to Patients With Alopecia Areata (COMPLETED) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Grape Seed Extract Natural product In Vitro Study Grapeseed procyanidin promotes proliferation of hair follicle cells. -…	Botanical	Preclinical	Emerging	7	2 trials View evidence Registry trials NCT07556016 — Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Men After 3 and 6 Months (ACTIVE_NOT_RECRUITING) NA NCT06174441 — The Effect of 24-week Dietary Intake of Food Supplements on Hair (COMPLETED) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Biochanin a Natural product Human Study An herbal extract combination (Biochanin A, Acetyl tetrapeptide-3, and…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Pumpkin Seed Oil/Meal Natural product Human Study Effect of pumpkin seed oil on hair growth in men with androgenetic alop…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Kimchi Natural product Human Study Kimchi and cheonggukjang probiotic product could promote hair growth an…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Beta Sitosterol Natural product Human Study The naturally occuring 5-alpha reductase inhibits Beta Sitosterol and S… An extract of Hydrangea shows promise in suppressing TGF-beta, which ma…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Saw Palmetto Natural product Human Study The naturally occuring 5-alpha reductase inhibits Beta Sitosterol and S…	Nutraceutical	Preclinical	Emerging	0	8 trials View evidence Registry trials NCT05332743 — Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair (COMPLETED) NA NCT06060834 — Impact of a Topical Cosmetic Product on Women's Hair (COMPLETED) NA NCT06174441 — The Effect of 24-week Dietary Intake of Food Supplements on Hair (COMPLETED) NA NCT05339958 — Nutraceutical Supplement With Standardized Botanicals in Males With Thinning Hair (COMPLETED) NA NCT03206567 — Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair (COMPLETED) NA NCT06920758 — A 6-month, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of USPlus DERM to Promote Hair Growth in Men and Women With Self-perceived Thinning Hair. (ACTIVE_NOT_RECRUITING) NA NCT06841458 — Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers (RECRUITING) NA NCT04048031 — Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair (COMPLETED) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Watercress Natural product Human In Vitro, Human Study These findings highlighted the potential use of watercress extract for…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Asiasari Radix Natural product Animal Study Asiasari radix has hair growth-promoting potential in treating hair los…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Cuscuta Reflexa Natural product Animal Study C. reflexa and its isolate is useful in treatment of androgen-induced a…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Ellagic Acid Natural product Animal Study Ellagic acid inhibits dihydrotestosterone-induced ferroptosis and promo…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Henna Natural product Animal Study Therapeutic effect of Impatiens balsamina, Lawsonia inermis L. and Henn…	Nutraceutical	Preclinical	Emerging	0	4 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Thujae Occidentalis Natural product Animal Study Thujae occidentalis inhbits 5-alpha reductase activity suggesting it ma…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Policosanol Natural product Review Anti-androgenetic alopecia effect of policosanol from Chinese wax by re…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Apigenin Natural product In Vitro Study Apigenin simulates hair growth in an in vitro model.	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Guava Natural product In Vitro Study Guava leaf extract as bioactive substances for anti-androgen and antiox…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Perilla Natural product Review Perilla frutescens: A rich source of pharmacological active compounds.	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Black Pepper Natural product Black pepper contains compounds, including piperine, which have 5-alpha…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network